Neogenomics Inc (NEO) 5.19 $NEO
Scheduled Conference Calls and Product Launches - Research Reports on Anika Therapeutics, NeoGenomics, HeartWare, Sangamo and Dyax
PR Newswire - Wed Jul 23, 7:40AM CDT
Today, Analysts Review released its research reports regarding Anika Therapeutics, Inc. (NASDAQ: ANIK), NeoGenomics, Inc. (NASDAQ: NEO), HeartWare International Inc (NASDAQ: TWR), Sangamo BioSciences, Inc. (NASDAQ: SGMO) and Dyax Corp (NASDAQ: DYAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5011-100free.
Why NeoGenomics, Inc. Stock Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Jul 17, 1:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of NeoGenomics , a cancer-focused provider of...
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Why NeoGenomics (NEO) Stock Is Up Today
at The Street - Thu Jul 17, 10:30AM CDT
NeoGenomics (NEO) is gaining Thursday after beating analysts' expectations for revenue in the second quarter.
NeoGenomics Reports Record Revenues of $20.7 Million on 40% Test Volume Growth and Expanding Gross Margins for the Second Quarter 2014
PR Newswire - Thu Jul 17, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the second quarter of 2014.
NeoGenomics to Host Second Quarter 2014 Earnings Webcast Live on Thursday, July 17, 2014
ACCESSWIRE - Wed Jul 16, 3:15PM CDT
Fort Myers, FL / ACCESSWIRE / July 16, 2014 / NeoGenomics, Inc. (NASDAQ:NEO) will host a live webcast to discuss the results of the second quarter 2014, to be held Thursday, July 17, 2014 at 11:00 AM Eastern Time.
NeoGenomics Expands Next Generation Sequencing Services and Offers 23 Different Profiles for Various Hematologic and Solid Cancers
PR Newswire - Fri Jul 11, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today it has launched 23 new and innovative NeoTYPE(TM) Cancer Profiles based on next-generation sequencing (NGS). These new advanced cancer-profiling tools offer oncologists and pathologists a more targeted and comprehensive ability to tailor cancer testing to an individual patient's needs than has ever been available before.
NeoGenomics Completes Acquisition of Path Logic
PR Newswire - Tue Jul 08, 3:37PM CDT
NeoGenomics, Inc. (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, today announced that it has acquired Path Labs, LLC d/b/a Path Logic. Path Logic is a leading provider of specialized anatomic pathology services to Hospitals and physicians in Northern California. Path Logic provides high-quality Anatomic Pathology services with significant expertise in the sub-specialties of renal pathology, dermatopathology, women's health and gastrointestinal and genitourinary pathology.
Why NeoGenomics (NEO) Stock Is Surging Today
at The Street - Mon Jul 07, 2:12PM CDT
Craig-Hallum set a "buy" rating on NeoGenomics (NEO) and increased its price target on the stock to $8 from $5.
Orphan Drug Designations, Financial Results, Board Elections, and Raised Financial Guidance - Analyst Notes on Agios, Alder, Healthways, NeoGenomics and Sequenom
PR Newswire - Wed Jul 02, 5:10AM CDT
Today, Analysts Review released its analysts' notes regarding Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Healthways Inc. (NASDAQ: HWAY), NeoGenomics Inc. (NASDAQ: NEO) and Sequenom Inc. (NASDAQ: SQNM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4351-100free.
NeoGenomics Raises Guidance and Projects 30% Year-Over-Year Revenue Growth in Quarter 2, 2014
PR Newswire - Mon Jun 23, 7:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, announced today that it was raising its previously issued revenue guidance for Quarter 2, 2014. The Company now expects revenue of approximately $20.0 - $20.5 million for the second quarter of 2014 compared with its previous estimate of $18.8 - $19.3 million. The Company also reaffirmed its previously issued earnings per share guidance of $0.00 - $0.01 for the quarter.
NeoGenomics Schedules its Q2 2014 Earnings Release for July 17, 2014
PR Newswire - Wed Jun 18, 10:06AM CDT
NeoGenomics, Inc. (NASDAQ: NEO)announced today that it plans to release its second quarter 2014 financial results on Thursday July 17, 2014.
4 Stocks Under $10 Making Big Moves
at The Street - Wed Apr 02, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
NeoGenomics Announces Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome
PR Newswire - Tue Mar 18, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched the first two of a series of next generation cancer profiling tests. These tests are designed for profiling myelodysplastic syndrome (MDS) and solid tumor cancers. Additional cancer-type specific next generation tests are currently being validated and are scheduled for launch over the next several months.
NeoGenomics Reports Record Revenue of $18.3 Million, Adjusted EBITDA of $2.7 Million and Net Income of $0.02 per Share for the Fourth Quarter 2013
PR Newswire - Wed Feb 19, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year of 2013.
W&T Offshore Announces Year-End 2013 Reserves And Production, 2014 Capital Budget And Provides An Operations Update
PR Newswire - Fri Feb 14, 5:30AM CST
W&T Offshore, Inc. (NYSE: WTI) reported that the Company replaced in excess of 100% of 2013 production, that year-end 2013 SEC proved reserves(1) were 117.7 million barrels of oil equivalent ("MMBoe"
, and the pre-tax present value of these proved reserves discounted at 10%(1) ("PV-10" was $2.5 billion. In addition, it announced that its Board of Directors has approved a 2014 capital expenditure budget of $450 million, excluding acquisitions. The Company has also provided production for 2013 and an operational update for the fourth quarter of 2013 and early 2014.
4 Health Care Stocks Under $10 to Watch
at The Street - Fri Jan 31, 6:00AM CST
Keep these under-$10 health care stocks on your radar.
NeoGenomics Launches 22 New Cancer Genomic Tests Designed for Actionable Profiling of Various Hematologic and Solid Cancers
PR Newswire - Thu Jan 30, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor.
NeoGenomics Schedules its Q4 2013 and Full Year 2013 Earnings Release for February 19, 2014
PR Newswire - Fri Jan 17, 1:20PM CST
NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its fourth quarter 2013 and full year 2013 financial results on Wednesday, February 19, 2014.
3 Health Care Stocks Under $10 Moving Higher
at The Street - Fri Jan 10, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Scheduled Conference Calls and Product Launches - Research Reports on Anika Therapeutics, NeoGenomics, HeartWare, Sangamo and Dyax
PR Newswire - Wed Jul 23, 7:40AM CDT
Today, Analysts Review released its research reports regarding Anika Therapeutics, Inc. (NASDAQ: ANIK), NeoGenomics, Inc. (NASDAQ: NEO), HeartWare International Inc (NASDAQ: TWR), Sangamo BioSciences, Inc. (NASDAQ: SGMO) and Dyax Corp (NASDAQ: DYAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5011-100free.
Why NeoGenomics, Inc. Stock Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Jul 17, 1:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of NeoGenomics , a cancer-focused provider of...
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Why NeoGenomics (NEO) Stock Is Up Today
at The Street - Thu Jul 17, 10:30AM CDT
NeoGenomics (NEO) is gaining Thursday after beating analysts' expectations for revenue in the second quarter.
NeoGenomics Reports Record Revenues of $20.7 Million on 40% Test Volume Growth and Expanding Gross Margins for the Second Quarter 2014
PR Newswire - Thu Jul 17, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the second quarter of 2014.
NeoGenomics to Host Second Quarter 2014 Earnings Webcast Live on Thursday, July 17, 2014
ACCESSWIRE - Wed Jul 16, 3:15PM CDT
Fort Myers, FL / ACCESSWIRE / July 16, 2014 / NeoGenomics, Inc. (NASDAQ:NEO) will host a live webcast to discuss the results of the second quarter 2014, to be held Thursday, July 17, 2014 at 11:00 AM Eastern Time.
NeoGenomics Expands Next Generation Sequencing Services and Offers 23 Different Profiles for Various Hematologic and Solid Cancers
PR Newswire - Fri Jul 11, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today it has launched 23 new and innovative NeoTYPE(TM) Cancer Profiles based on next-generation sequencing (NGS). These new advanced cancer-profiling tools offer oncologists and pathologists a more targeted and comprehensive ability to tailor cancer testing to an individual patient's needs than has ever been available before.
NeoGenomics Completes Acquisition of Path Logic
PR Newswire - Tue Jul 08, 3:37PM CDT
NeoGenomics, Inc. (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, today announced that it has acquired Path Labs, LLC d/b/a Path Logic. Path Logic is a leading provider of specialized anatomic pathology services to Hospitals and physicians in Northern California. Path Logic provides high-quality Anatomic Pathology services with significant expertise in the sub-specialties of renal pathology, dermatopathology, women's health and gastrointestinal and genitourinary pathology.
Why NeoGenomics (NEO) Stock Is Surging Today
at The Street - Mon Jul 07, 2:12PM CDT
Craig-Hallum set a "buy" rating on NeoGenomics (NEO) and increased its price target on the stock to $8 from $5.
Orphan Drug Designations, Financial Results, Board Elections, and Raised Financial Guidance - Analyst Notes on Agios, Alder, Healthways, NeoGenomics and Sequenom
PR Newswire - Wed Jul 02, 5:10AM CDT
Today, Analysts Review released its analysts' notes regarding Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Healthways Inc. (NASDAQ: HWAY), NeoGenomics Inc. (NASDAQ: NEO) and Sequenom Inc. (NASDAQ: SQNM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4351-100free.
NeoGenomics Raises Guidance and Projects 30% Year-Over-Year Revenue Growth in Quarter 2, 2014
PR Newswire - Mon Jun 23, 7:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, announced today that it was raising its previously issued revenue guidance for Quarter 2, 2014. The Company now expects revenue of approximately $20.0 - $20.5 million for the second quarter of 2014 compared with its previous estimate of $18.8 - $19.3 million. The Company also reaffirmed its previously issued earnings per share guidance of $0.00 - $0.01 for the quarter.
NeoGenomics Schedules its Q2 2014 Earnings Release for July 17, 2014
PR Newswire - Wed Jun 18, 10:06AM CDT
NeoGenomics, Inc. (NASDAQ: NEO)announced today that it plans to release its second quarter 2014 financial results on Thursday July 17, 2014.
4 Stocks Under $10 Making Big Moves
at The Street - Wed Apr 02, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
NeoGenomics Announces Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome
PR Newswire - Tue Mar 18, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched the first two of a series of next generation cancer profiling tests. These tests are designed for profiling myelodysplastic syndrome (MDS) and solid tumor cancers. Additional cancer-type specific next generation tests are currently being validated and are scheduled for launch over the next several months.
NeoGenomics Reports Record Revenue of $18.3 Million, Adjusted EBITDA of $2.7 Million and Net Income of $0.02 per Share for the Fourth Quarter 2013
PR Newswire - Wed Feb 19, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year of 2013.
W&T Offshore Announces Year-End 2013 Reserves And Production, 2014 Capital Budget And Provides An Operations Update
PR Newswire - Fri Feb 14, 5:30AM CST
W&T Offshore, Inc. (NYSE: WTI) reported that the Company replaced in excess of 100% of 2013 production, that year-end 2013 SEC proved reserves(1) were 117.7 million barrels of oil equivalent ("MMBoe"
, and the pre-tax present value of these proved reserves discounted at 10%(1) ("PV-10" was $2.5 billion. In addition, it announced that its Board of Directors has approved a 2014 capital expenditure budget of $450 million, excluding acquisitions. The Company has also provided production for 2013 and an operational update for the fourth quarter of 2013 and early 2014. 4 Health Care Stocks Under $10 to Watch
at The Street - Fri Jan 31, 6:00AM CST
Keep these under-$10 health care stocks on your radar.
NeoGenomics Launches 22 New Cancer Genomic Tests Designed for Actionable Profiling of Various Hematologic and Solid Cancers
PR Newswire - Thu Jan 30, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor.
NeoGenomics Schedules its Q4 2013 and Full Year 2013 Earnings Release for February 19, 2014
PR Newswire - Fri Jan 17, 1:20PM CST
NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its fourth quarter 2013 and full year 2013 financial results on Wednesday, February 19, 2014.
3 Health Care Stocks Under $10 Moving Higher
at The Street - Fri Jan 10, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
